{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:51:13Z","timestamp":1784310673360,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary central nervous system (CNS) T-cell lymphomas, such as anaplastic large-cell lymphoma (ALCL) with anaplastic lymphoma kinase (ALK) negativity, are relatively rare and aggressive. Despite the administration of high-dose methotrexate (HD-MTX) therapy, the prognosis remains pessimistic. We reported a 21-year-old male patient initially presented with headache and fever. Following surgical intervention, the pathological examination confirmed the diagnosis of ALK-negative ALCL, and the patient was in a critical postoperative condition, evidenced by a Glasgow Coma Scale (GCS) score ranging from 5 to 9. After undergoing chemotherapy with HD-MTX, CD30 and CD7-targeted chimeric antigen receptor T (CAR-T) cells were sequentially infused. The initial infusion dosage was 0.5\u00d710<jats:sup>6<\/jats:sup> cells per kilogram (kg) of body weight, which was subsequently adjusted to 1\u00d710<jats:sup>6<\/jats:sup> cells per kg. During this therapeutic process, grade 2 cytokine release syndrome (CRS) occurred. However, the CAR-T cells exhibited robust expansion in the peripheral blood, and the patient\u2019s level of consciousness improved significantly, as indicated by an increase in the GCS score to a range of 12 to 15. A 15-month follow-up assessment revealed no evidence of tumor recurrence, and the patient was able to ambulate with the assistance of rehabilitation equipment. This case represents the first globally successful instance of treating ALK-negative primary central nervous system anaplastic large-cell lymphoma (PCNSALCL) with CAR-T therapy. It validates the feasibility and safety of the sequential CD30\/CD7 CAR-T therapy for rare CNS T-cell lymphomas, offering a novel treatment strategy for these conditions. Nevertheless, further long-term follow-up and evaluation are essential to determine its sustained efficacy and immunological implications.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1570214","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:34:20Z","timestamp":1753335260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhongqing","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.04.012","article-title":"Primary central nervous system lymphoma","volume":"63","author":"Ferreri","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.07.020","article-title":"Primary central nervous system T-cell lymphoma: An analysis from the surveillance, epidemiology, and end results program","volume":"79","author":"Long","year":"2020","journal-title":"J Clin Neurosci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological Malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27316","article-title":"CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40164-024-00584-6","article-title":"Chimeric antigen receptor-T cell therapy for T cell-derived hematological Malignancies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2024-196853","article-title":"CD7-targeted CAR-T cell therapy shows promising efficacy and safety in treating refractory\/relapsed peripheral T-cell lymphoma: Phase I clinical trial","volume":"144","author":"Yang","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847808.59949.f6","article-title":"P1236: Efficacy and toxicity for CD7 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory T-cell lymphoma","volume":"6","author":"Hu","year":"2022","journal-title":"HemaSphere"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e006959","DOI":"10.1136\/jitc-2023-006959","article-title":"Patient-reported outcomes in CD30-directed CAR-T cells against relapsed\/refractory CD30+ lymphomas","volume":"11","author":"Tschernia","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174358","article-title":"Clinical features and prognostic factors for primary anaplastic large cell lymphoma of the central nervous system: a systematic review","volume":"13","author":"Hirano","year":"2021","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(99)90253-8","article-title":"Primary anaplastic large cell lymphoma of the central nervous system","volume":"30","author":"Abdulkader","year":"1999","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2013.110","article-title":"Clinical presentation of anaplastic large-cell lymphoma in the central nervous system","volume":"1","author":"Nomura","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5858\/132.11.1830","article-title":"Primary central nervous system lymphoma","volume":"132","author":"Bhagavathi","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021115","article-title":"Primary anaplastic large cell lymphoma of the central nervous system in a child: A case report","volume":"99","author":"Feng","year":"2020","journal-title":"Medicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK\u2013 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200304000-00008","article-title":"Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression","volume":"27","author":"George","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2014.06.005","article-title":"Anaplastic large cell lymphoma presenting as a cerebellar mass","volume":"7","author":"Geetha","year":"2014","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood.V96.9.2993","article-title":"Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki","year":"2000","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2176\/nmccrj.cr.2020-0234","article-title":"Primary central nervous system T-cell lymphoma as methotrexate-associated lymphoproliferative disorders: case report","volume":"8","author":"Kawano","year":"2021","journal-title":"NMC Case Rep J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2018.07.021","article-title":"MRI of intracranial intraventricular lesions","volume":"52","author":"Muly","year":"2018","journal-title":"Clin Imaging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/63.4.275","article-title":"Meningioma pathology, genetics, and biology","volume":"63","author":"Lamszus","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"B26","article-title":"Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system","volume":"17","author":"Carlson","year":"1996","journal-title":"AJNR Am J Neuroradiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2020.1839630","article-title":"ALK-negative CNS anaplastic large cell lymphoma: case report and review of literature","volume":"37","author":"Lannon","year":"2023","journal-title":"Br J Neurosurg"},{"key":"B28","first-page":"2006-2006","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)","author":"Nayak","year":"2024"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03246-w","article-title":"Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis","volume":"72","author":"Lv","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/medicina57040334","article-title":"Human allogeneic bone marrow-derived mesenchymal stem cell therapy for cerebellar ataxia: A case report","volume":"57","author":"Ko","year":"2021","journal-title":"Medicina (Kaunas)"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1674954","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1570214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:25:06Z","timestamp":1755851106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1570214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1570214"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1570214","relation":{"correction":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1674954","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1570214"}}